首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Aryl-45-dihydro-1H-pyrazole-1-carboxamide Derivatives Bearing a Sulfonamide Moiety Show Single-digit Nanomolar-to-Subnanomolar Inhibition Constants against the Tumor-associated Human Carbonic Anhydrases IX and XII
【2h】

Aryl-45-dihydro-1H-pyrazole-1-carboxamide Derivatives Bearing a Sulfonamide Moiety Show Single-digit Nanomolar-to-Subnanomolar Inhibition Constants against the Tumor-associated Human Carbonic Anhydrases IX and XII

机译:带有磺酰胺基团的芳基-45-二氢-1H-吡唑-1-羧酰胺衍生物显示出对肿瘤相关的人类碳酸酐酶IX和XII的个位数纳摩尔至亚纳摩尔抑制常数。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A series of new 3-phenyl-5-aryl- -(4-sulfamoylphenyl)-4,5-dihydro-1 -pyrazole-1-carboxamide derivatives was designed here, synthesized, and studied for carbonic anhydrase (CAs, EC 4.2.1.1) inhibitory activity against the human (h) isozymes I, II, and VII (cytosolic, off-target isoforms), and IX and XII (anticancer drug targets). Generally, CA I was not effectively inhibited, whereas effective inhibitors were identified against both CAs II (K s in the range of 5.2–233 nM) and VII (K s in the range of 2.3–350 nM). Nonetheless, CAs IX and XII were the most susceptible isoforms to this class of inhibitors. In particular, compounds bearing an unsubstituted phenyl ring at the pyrazoline 3 position showed 1.3–1.5 nM K s against CA IX. In contrast, a subset of derivatives having a 4-halo-phenyl at the same position of the aromatic scaffold even reached subnanomolar K s against CA XII (0.62–0.99 nM). Docking studies with CA IX and XII were used to shed light on the derivative binding mode driving the preferential inhibition of the tumor-associated CAs. The identified potent and selective CA IX/XII inhibitors are of interest as leads for the development of new anticancer strategies.
机译:本文设计,合成了一系列新的3-苯基-5-芳基-(4-氨磺酰基苯基)-4,5-二氢-1-吡唑-1-羧酰胺衍生物,并研究了碳酸酐酶(CAs,EC 4.2。 1.1)对人(h)同工酶I,II和VII(胞质,脱靶同工型)以及IX和XII(抗癌药物靶标)的抑制活性。通常,CA I不能被有效抑制,而针对CA II(Ks在5.2-233 nM范围内)和VIIs(Ks在2.3-350 nM范围内)均被鉴定为有效抑制剂。但是,CA IX和XII是这类抑制剂最易受感染的同工型。特别是,在吡唑啉3位上带有未取代苯环的化合物对CA IX的显示为1.3–1.5 nM K s。相反,在芳香族骨架的相同位置上具有4-卤代苯基的衍生物的一个子集甚至达到了针对CA XII的亚纳摩尔K s(0.62-0.99 nM)。与CA IX和XII的对接研究用于阐明驱动肿瘤相关CA优先抑制的衍生物结合模式。鉴定出的有效和选择性的CA IX / XII抑制剂作为开发新的抗癌策略的先导是令人感兴趣的。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号